Successful treatment with rasburicase of a tophaceous gout in a patient allergic to allopurinol

Nature Clinical Practice Rheumatology

Volumn 2, Issue 6, 2006, Pages 338-342

  Richette, Pascal ^a   Bardin, Thomas ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Allergy; Allopurinol; Gout; Intolerant; Rasburiscase

Indexed keywords

ALLOPURINOL; BICARBONATE; BISOPROLOL; CODEINE; COLCHICINE; DICLOFENAC; FENOFIBRATE; METHYLPREDNISOLONE; OMEPRAZOLE; PARACETAMOL; PREDNISOLONE; RASBURICASE; URIC ACID;

ADULT; ANGIONEUROTIC EDEMA; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DISEASE ASSOCIATION; DISEASE DURATION; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; FEMALE; FOOT RADIOGRAPHY; GOUT; HAND RADIOGRAPHY; HUMAN; INTERSTITIAL NEPHRITIS; KIDNEY FAILURE; LABORATORY TEST; LOW DRUG DOSE; NEPHROLITHIASIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SUBCUTANEOUS NODULE; THERAPY RESISTANCE; URIC ACID BLOOD LEVEL; URIC ACID STONE; URTICARIA;

ALLOPURINOL; ARTHRITIS, GOUTY; DIAGNOSIS, DIFFERENTIAL; FEMALE; FINGER JOINT; GOUT SUPPRESSANTS; HUMANS; HYPERSENSITIVITY; MIDDLE AGED; RECOMBINANT PROTEINS; SEVERITY OF ILLNESS INDEX; URATE OXIDASE;

EID: 33744963408     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0214     Document Type: Article

References (15)

1. Terkeltaub RA (2003) Clinical practice. Gout. N Engl J Med 349: 1647-1655
2. Rott KT and Agudelo CA (2003) Gout. JAMA 289: 2857-2860
3. Choi HK et al. (2005) Pathogenesis of gout. Ann Intern Med 143: 499-516
4. Puig JG et al. (1991) Female gout. Clinical spectrum and uric acid metabolism. Arch Intern Med 151: 726-732
5. De Souza AW et al. (2005) Female gout: Clinical and laboratory features. J Rheumatol 32: 2186-2188
6. Johnson RJ et al. (2005) Essential hypertension, progressive renal disease, and uric acid: A pathogenetic link? J Am Soc Nephrol 16: 1909-1919
7. Bieber JD and Terkeltaub RA (2004) Gout: On the brink of novel therapeutic options for an ancient disease. Arthritis Rheum 50: 2400-2414
8. Fam AG and Assaad D (1997) Intradermal urate tophi. J Rheumatol 24: 1126-1131
9. Vazquez-Mellado J et al. (1999) Intradermal tophi in gout: A case-control study. J Rheumatol 26: 136-140
10. Jones AC et al. (1992) Diseases associated with calcium pyrophosphate deposition disease. Semin Arthritis Rheum 22: 188-202
11. Wortmann RL (2005) Recent advances in the management of gout and hyperuricemia. Curr Opin Rheumatol 17: 319-324
12. Bardin T (2004) Current management of gout in patients unresponsive or allergic to allopurinol. Joint Bone Spine 71: 481-485
13. Hung SI et al. (2005) HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 102: 4134-4139
14. Vogt B (2005) Urate oxidase (rasburicase) for treatment of severe tophaceous gout. Nephrol Dial Transplant 20: 431-433
15. Becker MA et al. (2004) Febuxostat, a novel nonpurine selective inhibitor of xanthine oxydase, therapy in allopurinol intolerant patients [abstract]. Arthritis Rheum 50 (Suppl): S803